Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells

Cell Death Differ. 1999 Apr;6(4):351-61. doi: 10.1038/sj.cdd.4400499.

Abstract

U937 leukemic cells treated for 24 h with 16 nM 12-O-tetradecanoylphorbol 13-acetate (TPA), that induces their macrophagic terminal differentiation, become resistant to etoposide-induced apoptosis. Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels. All these events are inhibited in TPA-differentiated U937 cells that are also resistant to vinblastine-induced and Fas-mediated cell death. Interestingly, these cells are not inherently resistant to apoptosis induction. Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels. All these events are not observed in undifferentiated cells treated in similar conditions. These results indicate that the apoptotic pathway that involves the release of cytochrome c from mitochondria and the cleavage of procaspases remains functional in TPA-differentiated cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology
  • Apoptosis / drug effects*
  • Carcinogens / pharmacology*
  • Caspase 2
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases / metabolism
  • Cell Adhesion / drug effects
  • Cell Differentiation / drug effects
  • Cycloheximide / pharmacology
  • Cytochrome c Group / metabolism
  • Enzyme Precursors / metabolism
  • Etoposide / pharmacology
  • Fas Ligand Protein
  • Humans
  • Membrane Glycoproteins / metabolism
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins / metabolism
  • Protein Synthesis Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Tetradecanoylphorbol Acetate / pharmacology*
  • U937 Cells
  • Vinblastine / pharmacology
  • bcl-X Protein

Substances

  • Antineoplastic Agents, Phytogenic
  • BCL2L1 protein, human
  • Carcinogens
  • Cytochrome c Group
  • Enzyme Precursors
  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins
  • Protein Synthesis Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-X Protein
  • Vinblastine
  • Etoposide
  • Cycloheximide
  • CASP3 protein, human
  • CASP8 protein, human
  • CASP9 protein, human
  • Caspase 2
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases
  • Tetradecanoylphorbol Acetate